Skip to main content
OpenTrials
Completed

NCT Number: NCT05364203

Interest of Immersive Virtual Reality on Stress During Botulinum Toxin Injections in Spasticity (RVTOX)

The main objective of the study is to investigate the effect of exposure to a virtual reality session during botulinum toxin injections on injection-induced stress.

The secondary objectives are to study the effect of exposure to a virtual reality session during botulinum toxin injections, on the pain induced by the injection. And study the evolution of the effects of virtual reality with the repetition of the sessions.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Botulinum toxin injections is very frequently used in the treatment of spasticity after central neurological damage (stroke, multiple sclerosis, spinal cord injury, head trauma). The injections may be painful and the tolerance of the injections varies from one patient to another. The pain felt during the injection causes in most patients great stress during the injection.

Virtual reality is a video technique with 360 ° vision simulating the physical presence of the patient in an "existing" environment outside the hospital setting. This technique has been used in painful procedures but only one publication, in pediatrics, has shown a decrease in pain and agitation during botulinum toxin injections.

The hypothesis of this research is that an immersive virtual reality system can, in adults, reduce stress and the painful experience of botulinum toxin injections.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patient, male or female, suffering from spasticity of neurological origin (multiple sclerosis, stroke, head trauma, etc.) and eligible for treatment by botulinum toxin injection
  • Able to give an informed consent to participate in research
  • Affiliation to Social Security.

Exclusion criteria

  • Contraindication to virtual reality (epilepsy, schizophrenia, strabismus, amblyopia, anisometropia, local contraindication to wearing a helmet (lesion of the face or the skull)
  • Major cognitive disorders
  • Any medical condition deemed by the investigator to be incompatible with the research.
  • Indication of sedation by MEOPA during botulinum toxin injection sessions.
  • Patients who have already experienced virtual reality
  • Drug treatment or medical condition that may affect heart rate variability
  • Pregnant or breastfeeding women
  • Patients under safeguard of justice
  • Refusal of participation.

Treatment and study plan

DEEPSEN virtual reality mask

Device

DEEPSEN virtual reality mask with 360 ° vision. The audio-visual content will be chosen by the patient.

Primary outcomes

  1. Heart rate variability (HRV) before injection and during the injections

    Time frame: during the procedure

    The stress measurement is carried out using a watch and a belt (heart rate monitor) which, thanks to several parameters, will allow us to carry out an HRV analysis on the KUBIOS software.

Secondary outcomes

  1. Effect on the pain induced by the injection

    Time frame: during the procedure

    At the end of the injections, the doctor asks the patient to give a score between 0 (no pain) and 10 (the worst pain), in order to give an idea of the pain felt during the botulinum toxin injections.

  2. Quality of the conditions for performing botulinum toxin injections

    Time frame: during the procedure

    Estimate by the doctor immediately after the end of the session [by a simple numerical scale (ENS) ranging from 0 ("extremely bad conditions") to 10 ("extremely good conditions")] or [on a 5-point Likert type scale points (conditions extremely bad/poor/neither bad nor good/good/extremely good)]

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Registry information

Official study title

Interest of Immersive Virtual Reality on Stress During Botulinum Toxin Injections in Spasticity

Acronym: RVTOX

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
May 6, 2022
Registry last updated
Sep 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.